Lunai Bioworks (LNAI) Free Cash Flow (2011 - 2026)
Lunai Bioworks (LNAI) posted quarterly Free Cash Flow of -$1.0 million for Q1 2026, up 30.97% year-over-year from -$784064.5 in Q1 2025, and up 4.14% quarter-over-quarter from -$1.1 million in Q4 2025.
Lunai Bioworks (LNAI) Free Cash Flow (2011 - 2026) Analysis & Trends
Lunai Bioworks' Free Cash Flow history runs 16 years deep, the most recent figure standing at -$1.0 million for Q1 2026.
- In Q1 2026, Free Cash Flow rose 30.97% year-over-year to -$1.0 million; the TTM figure through Mar 2026 stood at -$5.3 million (up 38.14% YoY), while the FY2025 annual figure was -$7.9 million, up 28.68% from the prior year.
- Free Cash Flow for Q1 2026 stood at -$1.0 million, up from -$1.1 million in the prior quarter.
- The five-year high for Free Cash Flow was -$1.0 million in Q1 2026, with the low at -$3.6 million in Q4 2022.
- The 5-year median for Free Cash Flow is -$2.6 million (2024), against an average of -$2.3 million.
- Peak annual rise in Free Cash Flow reached 76.65% in 2022, while the deepest fall reached 19.47% in 2022.
- Lunai Bioworks' Free Cash Flow stood at -$3.6 million in 2022, then grew by 11.4% to -$3.1 million in 2023, then advanced by 18.65% to -$2.6 million in 2024, then surged by 58.15% to -$1.1 million in 2025, then increased by 4.14% to -$1.0 million in 2026.
- Business Quant data shows LNAI's Free Cash Flow at -$1.0 million in Q1 2026, -$1.1 million in Q4 2025, and -$1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Lunai Bioworks | 6.87 Mn | 3.72 Mn | 20,942.00 | -1.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.03 Mn |
| Mar 31, 2026 | -1.03 Mn |
| Dec 31, 2025 | -1.07 Mn |
| Dec 31, 2025 | -1.07 Mn |
| Sep 30, 2025 | -1.35 Mn |
| Sep 30, 2025 | -1.35 Mn |
| Jun 30, 2025 | -1.81 Mn |
| Jun 30, 2025 | -1.81 Mn |
| Mar 31, 2025 | -1.49 Mn |
| Mar 31, 2025 | -1.49 Mn |
| Dec 31, 2024 | -2.56 Mn |
| Dec 31, 2024 | -2.56 Mn |
| Sep 30, 2024 | -2.02 Mn |
| Sep 30, 2024 | -2.02 Mn |
| Jun 30, 2024 | -2.44 Mn |
| Jun 30, 2024 | -2.44 Mn |
| Mar 31, 2024 | -2.64 Mn |
| Mar 31, 2024 | -2.64 Mn |
| Dec 31, 2023 | -3.15 Mn |
| Dec 31, 2023 | -3.15 Mn |